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Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is
a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring
of vaccines using electronic health record (eHR) databases in Europe. Proof-of-concept studies were
designed to assess the proposed processes and system for generating the required evidence to perform
B/R assessment and near-real time monitoring of vaccines. We aimed to test B/R methodologies for vac-
cines, using the comparison of the B/R profiles of whole-cell (wP) and acellular pertussis (aP) vaccine for-
mulations in children as an example.
Methods: We used multi-criteria decision analysis (MCDA) to structure the B/R assessment combined
with individual-level state transition modelling to build the B/R effects table. In the state transition
model, we simulated the number of events in two hypothetical cohorts of 1 million children followed
from first pertussis dose till pre-school-entry booster (or six years of age, whichever occurred first), with
one cohort receiving wP, and the other aP. The benefits were reductions in pertussis incidence and com-
plications. The risks were increased incidences of febrile convulsions, fever, hypotonic-hyporesponsive
episodes, injection-site reactions and persistent crying. Most model parameters were informed by esti-
mates (coverage, background incidences, relative risks) from eHR databases from Denmark (SSI), Spain
(BIFAP and SIDIAP), Italy (Pedianet) and the UK (RCGP-RSC and THIN). Preferences were elicited from
clinical and epidemiological experts.
Results: Using state transition modelling to build the B/R effects table facilitated the comparison of dif-
ferent vaccine effects (e.g. immediate vaccine risks vs long-term vaccine benefits). Estimates from eHR
databases could be used to inform the simulation model. The model results could be easily combined
with preference weights to obtain B/R scores.
Conclusion: Existing B/R methodology, modelling and estimates from eHR databases can be successfully
used for B/R assessment of vaccines.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ic health
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The Accelerated Development of VAccine beNefit-risk Collabo-
ration in Europe project (ADVANCE), launched in 2013 and funded
by the Innovative Medicines Initiative (IMI), is a public-private
partnership aiming to develop and test a system for rapid
benefit-risk (B/R) assessment and near-real time monitoring of
vaccines in the post-marketing setting [1] (see Appendix for list
of consortium members). A series of proof-of-concept (POC) stud-
ies were designed to assess the proposed processes and system.
The present study aimed to test a methodology for the B/R assess-
ment of vaccines and assess the use of European electronic health
record (eHR) databases for informing the B/R assessment.
There are several methodologies for B/R assessments that can
support medical decision-making [2]. In particular, the B/R ‘effects
table’ is widely used following its introduction in European
Public Assessment Reports. However, other tools exist, including
frameworks, metrics, estimation and modelling techniques,
as well as preference elicitation techniques [2,3]. The
‘Pharmacoepidemiological Research on Outcome and Therapeutics’
(PROTECT) consortium completed pioneering work in identifying,
organising and appraising B/R assessment tools [4]. Based on their
experience drawn from eight case studies, they recommended a
systematic approach containing five generic steps; (1) planning,
(2) evidence gathering, (3) analysis, (4) exploration and (5) com-
munication, rather than a one-size-fits-all approach [5]. However,
up to now, most B/R methodologies have been developed for
medicinal products while the B/R assessment of vaccines may
require different methods [5].
When conducting a B/R assessment in a post-marketing setting,
different information sources can be used, including clinical trials,
observational studies and systematic literature reviews. Currently,
there is a growing interest in using large eHR databases to study
vaccine outcomes (e.g. Vaccine Safety Datalink [6], the Post-
Licensure Rapid Immunization Safety Monitoring programme [7]
and ADVANCE [1]) since these potentially enable real-world vac-
cine effects to be studied on a large scale in geographical diverse
settings.
To explore B/R assessment methodology for vaccines and the
use of large eHR databases for informing the B/R model, we com-
pared the B/R profiles of whole-cell (wP) and acellular pertussis
(aP) vaccine formulations in children prior to their pre-school-
entry booster as a test case. This test case was selected to mimic
the introduction of a new vaccine, where systematic monitoring
of changes in B/R profile over time would be needed. This POC
study was undertaken for system testing and not to inform clinical,
regulatory or public health decisions on pertussis vaccination.2. Methods
2.1. Benefit-risk analysis
We used multi-criteria decision analysis (MCDA) to structure
the B/R assessment following the PROTECT recommendations and
ISPOR guidelines [5,8,9]. MCDA provides a structured, stepwise
approach for the assessment and comparison of different treat-
ment alternatives for benefit and risk outcomes [10]. However,
the measures for the vaccine benefits (i.e., vaccine effectiveness
or impact) and vaccine risks (i.e. risk ratios or rate ratios) are differ-
ent, with typically the vaccine benefits being long-term and the
vaccine risks being immediate and short-term. To facilitate their
comparison, we used individual-based state transition modelling
with parameters informed by multi-country eHR database studies
on pertussis vaccination coverage, benefits and risks [11–13]. The
results of the state transition model were then combined withPlease cite this article as: K. Bollaerts, E. Ledent, T. de Smedt et al., ADVANCE s
teria decision analysis and individual-level state transition modelling, Vaccinepreference weights solicited from clinical and epidemiological
experts to obtain overall B/R scores.2.2. Multi-criteria decision analysis
Details on the different MCDA steps and their application are
given below.
Step 1: Establishment of the decision context
The test casewas the comparison of the B/R profiles of wP and aP
vaccine formulations in children prior to their pre-school-entry
booster (or six years of age, whichever occurred first) in Europe.
Vaccines containing wP have been available since the 1940s
whereas aP containing vaccines were developed and used from the
mid-1990s. Most European countries replaced wP with aP, and
Poland is theonly country in Europewhere awPvaccine formulation
is still included in the childhood vaccination programme [11].
Step 2: Identification of key benefit and risk criteria (value tree)
The initial value tree was discussed and agreed by clinical and
epidemiological experts from public health, vaccine manufacturers
and academia (Fig. 1). In the final tree, indirect effects were omit-
ted for simplicity, limb swelling was combined with other
injection-site reactions to avoid double-counting; and convulsions
were defined as febrile convulsions. The final value tree contained
reductions in pertussis and its complications (convulsions, pneu-
monia and death) as benefit outcomes and febrile convulsions,
fever, hypotonic-hyporesponsive episodes (HHE), injection-site
reactions (ISR) and persistent crying as risk outcomes.
Step 3: Identification of data sources
The parameters of the B/R model were based on results for
vaccination coverage, benefits and risks from the ADVANCE
multi-country eHR database studies where possible [11–13]. The
following databases were included in this study: SSI (Denmark),
BIFAP and SIDIAP (Spain) and RCGP RSC and THIN (UK), PEDIANET
(Italy). Detailed information on the databases can be found in
[11–14].
Step 4: Construction of the benefit-risk effects table
We used an individual-based state transition simulation model
to build the B/R effects table. For the participating countries (i.e.,
Denmark, Italy, Spain and the UK), we built two hypothetical
cohorts of 1,000,000 children followed from their first pertussis
dose until their pre-school booster (or six years of age). One cohort
was vaccinated with wP, the other with aP. Unvaccinated children
were not included as the B/R assessment focused on direct effects
only (Fig. 1). To avoid the impact of time-varying confounding or
changes in the background incidence rates on the wP-aP compar-
ison, the two hypothetical cohorts were identical with respect to
the age-specific background incidence rates, vaccination coverage
and age at vaccination. Only the vaccine type-specific parameters
(i.e., VE and RR) were varied between the aP and wP hypothetical
cohorts.
The parameters for the simulation model were informed by the
results from the ADVANCE multi-country eHR database studies on
pertussis vaccination coverage, benefits and risks with the excep-
tion of pertussis vaccine effectiveness and pertussis complication
incidence rates, which were not available when this B/R analysis
was undertaken [11–13,15–18]. Since the vaccination schedules
are different across countries, the dose-specific vaccination cover-
age and age at vaccination were kept country-specific whereas theystem testing: Benefit-risk analysis of a marketed vaccine using multi-cri-
, https://doi.org/10.1016/j.vaccine.2019.09.034
Fig. 1. Initial and final pertussis vaccination outcome trees. The outcomes that were not retained for the final outcome tree are shaded in grey. (aP: acellular pertussis
vaccines; wP: whole-cell pertussis vaccines; HHE: hypotonic-hyporesponsive episodes).
K. Bollaerts et al. / Vaccine xxx (xxxx) xxx 3background incidence rates and vaccine-type-specific RRs were
pooled across countries to increase precision. To take into
consideration age-related dependencies, a finely disaggregated
age-structure (monthly from first dose to age two and 3-monthly
afterwards) was used. Within each cohort, the expected number
of events for each outcome was estimated through Monte Carlo
simulation based on 1000 simulation draws. Median and 95%
uncertainty intervals were obtained to account for uncertainty in
model parameters. The simulation models were developed using
R version 3.4.0 [19]. The model input parameters are summarised
in Table 1.
Step 4.1: model input parameters: coverage
To reflect recent practice, most recent coverage estimates with
at least two years of follow up were obtained from the ADVANCE
coverage POC study (e.g. Denmark, Spain and UK: birth cohort
2010; Italy: birth cohort 2007) [11]. The 2- and 3-dose country-
specific coverage rates at 24 months old and the age at vaccination
were estimated for children who had received at least 1 dose
(Fig. 2).Please cite this article as: K. Bollaerts, E. Ledent, T. de Smedt et al., ADVANCE s
teria decision analysis and individual-level state transition modelling, VaccineStep 4.2: model input parameters: benefits
The incidence of pertussis in unvaccinated children was derived
from the incidence for those who had received only one dose (since
unvaccinated children were excluded from the database study) and
an estimate of the 1-dose vaccine effectiveness obtained from the
literature [12,16]. To reflect recent epidemiology, data from 2005
onwards were used to estimate age-specific pertussis incidences,
which were then pooled across databases using random effects
meta-analyses (Fig. 3) [20].
Step 4.3: model input parameters: risks
Baseline incidences (2005 onwards) were used from primary
care databases (BIFAP, RCGP RSC, THIN and PEDIANET) for fever,
ISR, persistent crying and somnolence (since these mild outcomes
are more likely to be reported in primary care); from the hospital
discharge database (SSI) for febrile convulsions (since this is a sev-
ere outcome likely to require hospitalisation); and from all data-
bases (primary care and hospital-based) for HHE (since this can
be a mild to severe outcome and therefore could be captured inystem testing: Benefit-risk analysis of a marketed vaccine using multi-cri-
, https://doi.org/10.1016/j.vaccine.2019.09.034
Table 1
Cohort simulation: overview of model parameters.
Parameter Mean [95% CI] Distribution Source(s)
aP wP
Coverage
Coverage at 24 months Fig. 2 Binomial distribution on number of vaccinated
children. Probability of being vaccinated is the
coverage at 24 mos.
[11]
Age at vaccination (in months) Fig. 2 Empirical distribution [11]
Benefits*
Pertussis
Age-specific incidence among
unvaccinated subjects (/100.000 py) (<6
years)
Fig. 3 Empirical: incidences in children with 1 dose only
divided by (1 – VEd1), VEd1 = 74%
[12,16]
Vaccine effectiveness – dose 1 0.66 [0.56; 0.71] 0.7 [0.62; 0.72] Log-normal on Rate ratio (RR = 1 – VE). Meta-
analysed 3-dose VE estimate multiplied with VE
ratio = 74.1%
[17,16]
Vaccine effectiveness – dose 2 0.83 [0.71; 0.89] 0.88 [0.84; 0.94] Log-normal on Rate ratio (RR = 1 – VE). Meta-
analysed 3-dose VE estimate multiplied with VE
ratio = 93.6%
[17,16]
Vaccine effectiveness – dose 3 0.89 [0.76; 0.95] 0.94 [0.89; 0.97] Log-normal on Rate ratio (RR = 1 – VE). Meta-
analysed estimate
[17]
Pertussis-related pneumonia (age-specific % of cases with
complications)
<6 months: 11.8%; 6–11 months: 8.6%;
1–4 years: 5.4%
Binomial distribution on number of cases with
complications. Probability of developing
complication is age-specific
[18]
Pertussis-related febrile seizures (age-specific % of cases
with complications)
<6 months: 1.4%; 6–11 months: 0.7%;
1–4 years: 1.2%
Binomial distribution on number of cases with
complications. Probability of developing
complication is age-specific
[18]
Pertussis-related deaths (age-specific % of cases with
complications)
<6 months: 0.8%; 6–11 months: 0.1%;
1–4 years: <0.1%
Binomial distribution on number of cases with
complications. Probability of developing
complication is age-specific
[18]
Risks**
Febrile convulsions
Age-specific baseline incidence (/1000 py) Fig. 4 Empirical [13]
Rate ratio (0-3d) – dose 1 0.89 [0.51; 1.57] 1.15 [0.63; 2.11] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-3d) – dose 2 0.94 [0.79; 1.11] 1.51 [0.71; 3.19] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-3d) – dose 3 2.19 [1.69; 2.83] 1.89 [1.55; 2.31] Log-normal on Rate ratio Meta-analysed estimate. [13]
Fever
Age-specific baseline incidence (/1000 py) Fig. 4 [13]
Rate ratio (0-3d) – dose 1 1.18 [1.08; 1.29] 1.92 [1.84; 2.00] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-3d) – dose 2 0.89 [0.81; 0.99] 1.47 [1.42; 1.54] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-3d) – dose 3 1.17 [0.98; 1.39] 1.85 [1.78; 1.92] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Hypotonic-hyporesponsive episodes
Age-specific baseline incidence (/1000 py) Fig. 4 [13]
Rate ratio (0-2d) – dose 1 2.72 [1.49; 4.96] 1.70 [1.30; 2.24] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-2d) – dose 2 1.42 [0.73; 2.79] 0.71 [0.36; 1.42] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-2d) – dose 3 1.65 [0.81; 3.39] 1.34 [1.01; 1.78] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Injection site reactions
Age-specific baseline incidence (/1000 py) Fig. 4 [13]
Rate ratio (0-2d) – dose 1 1.38 [1.15; 1.65] 2.12 [1.89; 2.38] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-2d) – dose 2 1.78 [1.09; 2.91] 2.42 [2.13; 2.74] Log-normal on Rate ratio. Meta-analysed estimate. [13]
Rate ratio (0-2d) – dose 3 1.65 [0.81; 3.39] 2.19 [1.95; 2.45] Log-normal on Rate ratio. Meta-analysed estimate. [13]
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were combined across databases to obtain pooled incidences,
which were subsequently smoothed using LOWESS (Fig. 4) [21].
The database-specific rate ratios of adverse events during the
exposure risk windows (by vaccine type and dose) were obtained
using a self-controlled case series method, which were subse-
quently pooled using random-effects meta-analyses (estimates in
Table 1) [13].
Steps 5–6: Definition of value functions and preference weights
Four clinical and epidemiological experts and three observers
attended a preference elicitationworkshop. The experts were volun-
teers from the ADVANCE consortium and the workshop was organ-
ised in compliance with ISPOR guidelines. After a face-to-face
training session on preference elicitation and practicing MCDA
swing-weighting using D-Sight software (www.d-sight.com) it was
agreed to simplify the preference elicitation as the participants
found the swing-weighting difficult to understand, especially when
non-linear value functionswere selected. It was therefore decided to
restrict to linear value functions and express, for each outcome, the
number of events that would be equivalent to one pertussis event
(with pertussis being considered as the most severe outcome). For
each outcome, the lower limit of the linear value function was
defined as theminimum lower limit of the 95% uncertainty intervals
of the number of events in both the hypothetical wP and aP cohort
whereas the upper limit of the linear value function was defined
as the maximum upper limit of the 95% uncertainty intervals.
Step 7: Calculation of the benefit-risk scores
The overall B/R scores for the wP and aP formulations (BRj) were
calculated as follows:
BRj ¼
XI
i
wi 1
Nij minNi
maxNi minNi
 
 100
This represents a linear value function, with
Nij ¼ max minNi;minðNij ;maxNiÞ
 
; where Nij Nij is the median
number of events in the hypothetical cohort j for event type i,
whereminNi minNi andmaxNi maxNi are the lower and upper limit
of the linear value function and where wi wiis the preference
weight. The preference weights were standardized so their sum
was equal to one. This implies that the ‘perfect’ vaccine (with the
number of events Nij equal to its minimum minNi for each out-
come) would have a B/R score of 100. To have a robust central ten-
dency measure Nij not affected by outliers the median number of
events was chosen.
Step 8: Performing sensitivity analyses
The impact of data uncertainty (as reflected by the 95% uncer-
tainty intervals of the number of events within the hypothetical
populations) was assessed through Monte Carlo simulation with
1000 simulation runs, assuming normal distributions for the num-
ber of events for each outcome. The impact of preference weights
was assessed by halving and doubling a single non-standardised
preference weight, while keeping the others constant, and then
standardising again.
3. Results
3.1. Model input parameters: coverage, benefits and risks
Almost all children in each of the four countries, who received
the first dose, completed the schedule, with the 3-dose coverageystem testing: Benefit-risk analysis of a marketed vaccine using multi-cri-
, https://doi.org/10.1016/j.vaccine.2019.09.034
Denmark (SSI, 2010) Italy (PEDIANET, 2007)
Spain (BIFAP and SIDIAP, 2010) UK (THIN and RCGP, 2010)
Fig. 2. Age-specific vaccination coverage rates (%) for children who received at least one dose, by dose and country (Denmark, Spain and UK: birth cohort 2010; Italy: birth
cohort 2007). The horizontal lines at the top indicate coverage for children aged 24 months for each dose. Data from [11].
6 K. Bollaerts et al. / Vaccine xxx (xxxx) xxxrate ranging from 95.7% to 97.9% (Fig. 2). The age at vaccination dif-
fered across countries in line with the national recommendations.
In Spain and the UK, all three doses were administered within the
first 10 months of life whereas in Italy and Denmark, the 3rd dose
was administered between 10 and 15 months of age. Pertussis inci-
dence after first dose (birth cohorts 2005 onwards) was highest in
children aged 2–3 months in all databases, although substantial
database heterogeneity existed, particularly for the two youngest
age groups (as indicated by the I2 statistic >75%) (Fig. 3). The
smoothed baseline risks are given in Fig. 4, clearly showing age
trends for all event types. The rate ratios of adverse events during
the exposure risk windows are given in Table 1.
3.2. Model results: benefit/risk effects table
The total expected number of events for vaccine-related plus -
unrelated outcomes, for both the wP and aP cohorts, are sum-
marised in Table 2. These estimates reflect the impact of vaccina-
tion on the total disease burden in the population assuming the
UK 2-dose and 3-dose vaccination coverage rates and age at vacci-
nation. Similar results were obtained assuming the vaccination
coverage rates and age at vaccination in Denmark, Italy and Spain
(Supplementary tables S1, S2 and S3).
3.3. Preference weights
Good consensus was reached among the participants for all
outcomes during the preference elicitation workshop (Fig. 5a).
The experts attributed higher preference weights to the benefitPlease cite this article as: K. Bollaerts, E. Ledent, T. de Smedt et al., ADVANCE s
teria decision analysis and individual-level state transition modelling, Vaccineof preventing pertussis than to the risks of vaccination, with an
averaged standardised preference weight of 92.8% for prevented
pertussis (Table 2, Fig. 5a).
3.4. Calculation of the benefit-risk scores
Prevented pertussis was shown to make the largest contribu-
tion to the overall B/R scores and was the most strongly discrimi-
nating factor between aP and wP (Fig. 5b).
3.5. Impact of data uncertainty
The Monte Carlo distributions of the overall B/R scores by vac-
cine type showed higher scores for wP than for aP, although there
was substantial overlap (Fig. 5c). Changes in the preference
weights for pertussis and febrile convulsions had the largest
impact on the overall B/R score for wP whereas changes in the pref-
erence weight for fever had the largest impact on the overall B/R
score for aP (Fig. 5d).
4. Discussion
These results demonstrated how existing B/R methodology can
be used for post-marketing B/R assessment of vaccines using evi-
dence on vaccination coverage, benefits, and risks that was
obtained through dedicated studies in eHR databases. We adopted
a structured approach for the B/R assessment as recommended by
the PROTECT project. To this end, we used MCDA and combined
MCDA with modelling to build the B/R effects table. Althoughystem testing: Benefit-risk analysis of a marketed vaccine using multi-cri-
, https://doi.org/10.1016/j.vaccine.2019.09.034
Fig. 3. Database-specific and meta-analysed pertussis incidence (/100.000 person-years (py)) among children who received one dose, by age group, 2005 onwards [12].
Estimates that were considered to be outliers, i.e. absolute value of the studentised residual was >2.5 (indicated by *) were excluded from the meta-analysis. Study
heterogeneity was investigated by the chi-squared test for heterogeneity, (p-values <0.05 indicate a significant amount of heterogeneity), and quantified using the I2 statistic
with low, moderate and high levels of heterogeneity corresponding to I2 values of 25%, 50% and 75%, respectively.
K. Bollaerts et al. / Vaccine xxx (xxxx) xxx 7MCDA has been used for vaccines before, to our knowledge, this is
the first time it has been combined with simulation modelling
techniques to build a B/R effects table [22].
More specifically, we used an individual-based state transition
simulation model to build the B/R effects table, expressed as the
total number of simulated events for the different benefit and risk
outcomes within the aP and wP hypothetical cohorts. Both cohorts
were identical with respect to the age-specific background inci-
dence rates and vaccination coverages. Only the vaccine type-
specific parameters (i.e., vaccine benefits and risks) were varied
between the two cohorts. This approach avoids the wP-aP compar-
ison being biased by time-varying confounding or changes in the
background incidence rates over time. Such bias would have
affected a simple comparison of event rates between populations
using aP and wP vaccines as the two vaccine types were used in
very distinct time periods. In addition, the simulation approach
facilitated the comparison of different vaccine effects, while
accounting for differences in age at vaccination, number of doses
given, age-specific baseline risks and differences in outcome-
specific risk windows. We simulated the total number of events
(i.e. vaccine-related and -unrelated) to assess the impact of vacci-Please cite this article as: K. Bollaerts, E. Ledent, T. de Smedt et al., ADVANCE s
teria decision analysis and individual-level state transition modelling, Vaccinenation on the total disease burden. We also complemented MCDA
with additional Monte Carlo simulations assessing the impact of
data uncertainty on the overall B/R scores, which broadened the
use of MCDA to decision-making under uncertainty. Additional
sensitivity analyses in which the preference weights were varied
enabled to assess the robustness of the B/R scores to changes in
preference weights. We used an individual-level state transition
simulation model to build the B/R effects table since we considered
only direct effects, however, dynamic transmission models could
have been used if indirect effects were to be considered as well.
Evidence that can be used to inform the post-marketing B/R
assessment models comes from diverse sources, potentially cover-
ing different geographical areas and populations, and is of variable
quality; here we assessed how evidence generated from eHR data-
bases could be used [23]. Compared with using available published
evidence, the approach we used has the advantage that different
model parameters can be consistently estimated with high levels
of granularity, within the same study population.
We have shown how preference weights can be easily com-
bined with the results from simulation models to obtain overall
B/R scores. We obtained preference weights from clinical andystem testing: Benefit-risk analysis of a marketed vaccine using multi-cri-
, https://doi.org/10.1016/j.vaccine.2019.09.034
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Fig. 4. Database-specific, pooled and LOWESS smoothed pooled estimates (with 95% CI) for age-specific baseline incidences (/1000 persons-years (py)) by risk outcome, 2005
onwards [13,21].
Table 2
Benefit/risk effects table, lower and upper limit of linear value functions and standardized averaged preference weights for the outcomes of interest.
Benefit/risk effects table Number of events* Median [95%
uncertainty intervals]
Linear value function Preference weights (%)
Event aP wP Lower limit Upper limit Averaged
Benefits (favourable effects)
Pertussis 1292 [686; 2467] 698 [440; 1186] 420 2500 92.8
Pertussis complications
Convulsions 15 [5; 30] 8 [2; 16] n.a. n.a. n.a.
Death 3 [0; 8] 2 [0; 5] n.a. n.a. n.a.
Pneumonia 101 [51; 188] 56 [34; 93] n.a. n.a. n.a.
Risks (unfavourable effects)
Febrile convulsions 69,702 [68,899; 70,564] 69,377 [68,730; 70,054] 68,000 71,000 3.8
Fever 539,768 [538,798; 540,702] 541,063 [540,102; 542,017] 540,000 541,500 2.4
Hypotonic-
hyporesponsive
episodes
2283 [2187; 2382] 2262 [2167; 2355] 2100 2400 0.9
Injection site
reactions
2819 [2709; 2930] 2896 [2782; 3003] 2700 3000 0.1
Persistent crying 25,477 [25,135; 25,859] 26,690 [26,268; 27,139] 25,000 27,500 <0.01
Somnolence 1783 [1689; 1877] 1799 [1704; 1917] 1600 2000 <0.01
* Cohort simulation model; number of events in a hypothetical cohort of 1 million children followed from first dose till pre-school booster; one cohort received aP, the other
wP. The vaccination coverage and age at vaccination are reflective of the UK. n.a. = data was not available at the time of the preference elicitation and these outcomes were
excluded from the overall B/R score.
8 K. Bollaerts et al. / Vaccine xxx (xxxx) xxxepidemiological experts as we believed they would have a good
understanding of both the benefits and risks of vaccination. We
solicited preferences using MCDA swing-weighting, which is one
of the most efficient methods of obtaining preference weights as
preferences can be solicited during a one-day workshop. However,
it requires training and a thorough understanding of the preferencePlease cite this article as: K. Bollaerts, E. Ledent, T. de Smedt et al., ADVANCE s
teria decision analysis and individual-level state transition modelling, Vaccineelicitation methodology by the participants. In our experience, the
participants found the use of strongly non-linear value functions in
the swing-weighting process difficult. Therefore, we simplified the
preference elicitation by asking the participants to express the
severity of each event by giving the number of outcome events that
would be equivalent to one pertussis event.ystem testing: Benefit-risk analysis of a marketed vaccine using multi-cri-
, https://doi.org/10.1016/j.vaccine.2019.09.034
Fig. 5. (a) Individual and averaged preference weights. (b) Overall B/R score and outcome contributions by vaccine formulation (aP vs wP). (c) Impact of data uncertainty:
distribution of the overall B/R scores by vaccine type obtained through Monte Carlo simulation. (d) Impact of preference weights: changes in the overall B/R scores when
doubling (red arrows) or halving (blue arrows) the preference weights one-at-the-time.
K. Bollaerts et al. / Vaccine xxx (xxxx) xxx 9Further discussions on when, from whom and how to elicit
preferences regarding vaccination is needed as preference elicita-
tion for vaccines raises many questions. Unlike drugs, vaccines
are mostly administered to healthy people, often to children as
part of a vaccination programme or mandate. This results in a very
low public tolerance for vaccination risks, despite the risks being
rare. On the other hand, the benefits of vaccination are often invis-
ible as the incidence of many vaccine-preventable diseases has
substantially decreased as a result of vaccination. In addition, some
vaccines have the potential to induce herd immunity, whereby
unvaccinated individuals are protected indirectly by those vacci-
nated, implying that the benefits are not necessarily borne by the
same individuals who take the risks.Please cite this article as: K. Bollaerts, E. Ledent, T. de Smedt et al., ADVANCE s
teria decision analysis and individual-level state transition modelling, VaccineNumerous methods for preference elicitation exist (e.g. time
trade-offs, discrete choice experiments, conjoint analyses) and
these can be used in diverse settings, such as focus groups or sur-
veys. Alternatively, it would be possible to use composite burden of
disease measures such as disability-adjusted life years (DALY) to
perform B/R assessments [24]. With this work, we only explored
preference elicitation using MCDA swing-weighting. Exploration
of different preference elicitation techniques for vaccines is needed
as well as more ethical discussions on comparing disease pre-
vented by vaccination and disease induced by vaccination.
In conclusion we have shown that it is feasible to use existing
B/R methodology and estimates from eHR databases to assess vac-
cines B/R successfully. We illustrated how modelling can be usedystem testing: Benefit-risk analysis of a marketed vaccine using multi-cri-
, https://doi.org/10.1016/j.vaccine.2019.09.034
10 K. Bollaerts et al. / Vaccine xxx (xxxx) xxxto build the B/R effects table expressed as the expected number of
events in hypothetical populations, which facilitates the compar-
ison of different vaccine effects.
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